{"title":"解决整形手术中的肥胖挑战——利拉鲁肽的作用。","authors":"K Staněk, R Billich, O Měšťák","doi":"10.48095/ccachp202386","DOIUrl":null,"url":null,"abstract":"literature supports the use of obesity pharmacotherapy, like liraglutide, for at least 12 months, showing a substantial percentage of weight loss. A phase 2 dose-ranging study and a series of four SCALE clinical trials provided further evidence for liraglutide’s effect on achieving and maintaining weight loss, and notable effects on improving glycemic parameters and cardiometabolic health [5].","PeriodicalId":7098,"journal":{"name":"Acta chirurgiae plasticae","volume":"65 2","pages":"86"},"PeriodicalIF":0.0000,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Addressing the obesity challenge in plastic surgery - the role of liraglutide.\",\"authors\":\"K Staněk, R Billich, O Měšťák\",\"doi\":\"10.48095/ccachp202386\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"literature supports the use of obesity pharmacotherapy, like liraglutide, for at least 12 months, showing a substantial percentage of weight loss. A phase 2 dose-ranging study and a series of four SCALE clinical trials provided further evidence for liraglutide’s effect on achieving and maintaining weight loss, and notable effects on improving glycemic parameters and cardiometabolic health [5].\",\"PeriodicalId\":7098,\"journal\":{\"name\":\"Acta chirurgiae plasticae\",\"volume\":\"65 2\",\"pages\":\"86\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2023-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Acta chirurgiae plasticae\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.48095/ccachp202386\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"Medicine\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Acta chirurgiae plasticae","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.48095/ccachp202386","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"Medicine","Score":null,"Total":0}
Addressing the obesity challenge in plastic surgery - the role of liraglutide.
literature supports the use of obesity pharmacotherapy, like liraglutide, for at least 12 months, showing a substantial percentage of weight loss. A phase 2 dose-ranging study and a series of four SCALE clinical trials provided further evidence for liraglutide’s effect on achieving and maintaining weight loss, and notable effects on improving glycemic parameters and cardiometabolic health [5].
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
